BI-9564

Modify Date: 2024-01-02 11:47:45

BI-9564 Structure
BI-9564 structure
Common Name BI-9564
CAS Number 1883429-22-8 Molecular Weight 353.415
Density 1.2±0.1 g/cm3 Boiling Point 519.9±50.0 °C at 760 mmHg
Molecular Formula C20H23N3O3 Melting Point N/A
MSDS N/A Flash Point 268.3±30.1 °C

 Use of BI-9564


BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 μM for BET family.

 Names

Name 4-{4-[(Dimethylamino)methyl]-2,5-dimethoxyphenyl}-2-methyl-2,7-naphthyridin-1(2H)-one
Synonym More Synonyms

 BI-9564 Biological Activity

Description BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 μM for BET family.
Related Catalog
Target

Kd: 20 nM (BRD9)

In Vitro BI-9564 (<5 μM) shows no activity against 324 kinases, and at 10 μM, an inhibition >40% is observed for only 2 out of 55 GPCRs. BI-9564 has antiproliferative effect on human acute myeloid eosinophilic leukemia cell line EOL-1, with EC50 of 800 nM[1]. BI-9564 shows Kd of 73 nM for BRD7, and is >10-fold more selective for BRD9 over the highly homologues bromodomain BRD7, which has been implied as a tumor suppressor and is down-regulated in cancer cells[2].
In Vivo BI-9564 (180 mg/kg, p.o.) shows attractive ADME/PK profiles for in vivo proof-of-concept studies. BI-9564 results in a modest but significant additional survival benefit of 2 days compared to survival of the control group in a xenograft model of human AML[1].
Cell Assay Cells are grown in 50 µL medium as specified by the supplier for 7 days starting with 500 and with 1000 cells per well of a 384 well plate in the presence of varying concentrations of compound before measuring viability via cellular ATP levels using the cell titer glow assay.
Animal Admin Female CIEA-NOG mice are engrafted intravenously with 1×107 EOL-1 AML cells stably expressing luciferase and GFP. Following injection of the cells animals are randomized based on body weight (n=10/group). Treatment starts on day 5 with either 0.5% Natrosol or BI-9564 formulated with 0.5% Natrosol. All doses are calculated relative to the mouse body weight on the treatment day. BI-9564 and the vehicle control are administered orally with a dosing volume of 10 mL/kg body weight. BI-9564 is administered daily from day 5 until 17 and from day 20 until 22. Dosing is interrupted on day 18 for two days as one mouse in the treatment group reaches -15% body weight loss. Tumour load is measured 2-3 times weekly based on bioluminescence imaging. The following scoring system is used: score 0, no clinical signs; score 1, tail or hind limb weakness. Animals are sacrificed based on severity criteria including appearance of paralysis score 1 and/or body weight loss exceeding -18%. In S54 this tumor mouse model body weight changes can occur due to increased tumor load or due to intolerability.
References

[1]. Martin LJ, et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.

[2]. Rezaul M. Karim, et al. An Advanced Tool To Interrogate BRD9. J. Med. Chem., 2016, 59 (10), pp 4459-4461

 Chemical & Physical Properties

Density 1.2±0.1 g/cm3
Boiling Point 519.9±50.0 °C at 760 mmHg
Molecular Formula C20H23N3O3
Molecular Weight 353.415
Flash Point 268.3±30.1 °C
Exact Mass 353.173950
LogP 2.05
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.590
Storage condition -20℃

 Synonyms

4-{4-[(Dimethylamino)methyl]-2,5-dimethoxyphenyl}-2-methyl-2,7-naphthyridin-1(2H)-on
2,7-Naphthyridin-1(2H)-one, 4-[4-[(dimethylamino)methyl]-2,5-dimethoxyphenyl]-2-methyl-
4-{4-[(Diméthylamino)méthyl]-2,5-diméthoxyphényl}-2-méthyl-2,7-naphtyridin-1(2H)-one
4-{4-[(Dimethylamino)methyl]-2,5-dimethoxyphenyl}-2-methyl-2,7-naphthyridin-1(2H)-one
BI-9564
Top Suppliers:I want be here



Get all suppliers and price by the below link:

BI-9564 suppliers


Price: $75/10mM*1mLinDMSO

Reference only. check more BI-9564 price